

**Listings of claims:**

1-10. (Canceled)

11. (Currently Amended) A compound ~~selected from:~~

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(1,3-benzodioxol-5-yl)ethyl]-(2*S*)-propylamine;

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-pyrid-4-ylethyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-pyrid-4-ylbutyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-~~

~~[4-(4-methoxyphenyl)butyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-~~

~~[2-(43-trifluoromethylphenyl)ethyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(4-fluorophenyl)ethyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-~~

~~[2-(3-methoxyphenyl)ethyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-~~


~~[2-(4-methoxyphenyl)ethyl]-(2*S*)-propylamine;~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-~~

~~[2-(4-methylsulphonylaminophenyl)ethyl]-(2*S*)-propylamine; and~~

~~2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.2]oct-2-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(1,3-benzodioxol-5-yl)ethyl]-(2*S*)-propylamine;~~  
or a salt, pro-drug or solvate thereof.

12. (Cancelled)
13. (Previously amended) A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to claim 1 and a pharmaceutically acceptable diluent or carrier.
14. (Withdrawn) A method of antagonising gonadotropin releasing hormone activity in a patient, the method comprising administering a compound, or salt, pro-drug or solvate thereof, according to claim 1 to a patient.
15. (Withdrawn) A method of treating and/or preventing a sex hormone related condition in a patient, the method comprising administering a compound according to claim 1, or salt, pro-drug or solvate thereof, to a patient.
16. (Withdrawn) A process for the preparation of a compound of Formula (I) as defined in Claim 1, comprising a process selected from (a) to (h) as follows:
- (a) Reaction of a compound of formula **XXXII** with a compound of formula  $H-R^5$ , to form a compound of Formula (I),




wherein  $X^1$  is selected from:


$$\begin{array}{c} R^{6a} \quad R^{6a} \\ \diagup \quad \diagdown \\ A \end{array} \quad \text{and} \quad \begin{array}{c} R^{6a} \quad R^{6a} \\ \diagup \quad \diagdown \\ A-L^1 \end{array}$$

;  $L^1$  is a displaceable group; and

$H-R^{5'}$  is selected from:



- (b) Reaction of a compound of formula **XXXIII** with a compound of formula  $H-R^{5''}$  to form a compound of Formula (I),



wherein  $X^2$  is selected from:

$$\begin{array}{c} R^{6a} \quad R^{6a} \quad R^{7a} \\ \diagup \quad \diagdown \quad | \\ A \quad \quad NH \end{array} \quad \text{and} \quad \begin{array}{c} R^{6a} \quad R^{6a} \\ \diagup \quad \diagdown \\ A-NH \end{array}$$

;  $L^2$  is a displaceable group and  $R^{7a}$  is selected from the definition of  $R^7$  or  $R^{22}$  above, and


$L^2-R^{5''}$  is selected from:




- (c) For compounds of Formula (I) wherein  $R^3$  is a group of Formula (IIa), (IIb), (IIc) or (IId) and  $R^7$  is other than part of a heterocyclic ring or hydrogen, reaction of a compound of Formula (I) wherein  $R^3$  is a group of Formula (IIa), (IIb), (IIc) or (IId) and  $R^7$  is hydrogen with a

group of formula  $L^3-R^{7a}$ , wherein  $R^{7a}$  is as defined above for  $R^7$  with the exclusion of hydrogen and  $L^3$  is a displaceable group;


- (d) For compounds of Formula (I) wherein  $R^3$  is a group of Formula (Ile) or (IIf) and  $R^{21}$  is other than hydrogen, reaction of a compound of Formula (I) wherein  $R^3$  is a group of Formula (Ile) or (IIf) and  $R^{21}$  is hydrogen with a group of formula  $L^4-R^{21a}$ , wherein  $R^{21a}$  is as defined above for  $R^{21}$  with the exclusion of hydrogen and  $L^4$  is a displaceable group;
- (e) For compounds of Formula (I) wherein  $R^3$  is a group of Formula (Ile) or (IIf) and  $R^{22}$  is other than hydrogen, reaction of a compound of Formula (I) wherein  $R^3$  is a group of Formula (Ile) or (IIf) and  $R^{22}$  is hydrogen with a group of formula  $L^5-R^{22a}$ , wherein  $R^{22a}$  is as defined above for  $R^{22}$  with the exclusion of hydrogen and  $L^5$  is a displaceable group;
- (f) For compounds of Formula (I) wherein  $R^3$  is a group of Formula (IIc) or (IIId) and



the group together forms an optionally substituted nitrogen-containing heterocyclic ring containing 4-7 carbons atoms, reaction of a compound of Formula XXXIVa or XXXIVb, with a compound of Formula  $L^6-K-R^8$ , wherein  $L^3$  is a displaceable group




XXXIVa




XXXIVb

- (g) For compounds of Formula (I) wherein  $R^3$  is a group of Formula (IIc) or (IIId), reaction of a compound of Formula XXXVa or XXXVb, with

a compound of Formula  $L^7-K''-R^8$ , wherein  $L^7$  is a displaceable group, and wherein the groups  $K'$  and  $K''$  comprise groups which when reacted together form  $K$ ,




XXXVa



XXXVb

;

- (h) reaction of a compound of Formula XXXVI with a compound of the formula  $L^8-R^5$ , wherein  $L^8$  is a displaceable group




XXXVI ;

and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.

17. (New) A compound of Formula (I),



Formula (I),

or a salt, pro-drug or solvate thereof, wherein


$R^1$  is hydrogen;

$R^2$  is 3,5-dimethylphenyl;

**M** is  $-\text{CH}_2\text{-O}-$ ;

**R**<sup>5</sup> is 2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy;

**R**<sup>3</sup> is Formula (IIb),



Formula (IIb),

wherein,

**R**<sup>6</sup> is hydrogen;

**R**<sup>6a</sup> is methyl;

**R**<sup>7</sup> is hydrogen;

**R**<sup>8</sup> is 1,3-benzodioxol-5-yl;

**A** is methylene; and

**B** is selected from ethylene and butylene.